M. Mei

发表

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.

G. Marcucci, I. Aldoss, S. Forman, 2021, Transplantation and cellular therapy.

Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.

Joshua T. Cohen, Jenelle M. Zambrano, E. Elkin, 2017, Journal of managed care & specialty pharmacy.

Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.

Joshua T. Cohen, Jenelle M. Zambrano, E. Elkin, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

D. Weisenburger, G. Marcucci, I. Aldoss, 2019, Clinical lymphoma, myeloma & leukemia.

Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?

A. Herrera, Tamer Othman, M. Mei, 2021, Current Hematologic Malignancy Reports.

Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices.

A. Salhotra, M. Mei, 2021, Cancer treatment and research.

Current and Emerging Therapies for Acute Myeloid Leukemia.

A. Stein, S. Otoukesh, M. Mei, 2021, Cancer treatment and research.

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

L. Kwak, S. Rosen, P. Martin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of Relapsed or Refractory Hodgkin Lymphoma with Second-Generation Antibody–Drug Conjugates: Focus on Brentuximab Vedotin

Robert Chen, Sandra H. Thomas, M. Mei, 2013, BioDrugs.

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma

A. Nademanee, J. Bading, J. Wong, 2021, Blood advances.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

J. Vose, Sonali M. Smith, R. Vij, 2018, Cancer.

The role of transplant in multiple myeloma.

G. Somlo, M. Mei, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.

S. de Vos, T. Kipps, Katti A. Jessen, 2021, NEJM evidence.

Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation

A. Krishnan, Jinhui Wang, T. Slavin, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

I. Flinn, K. Savage, M. Minden, 2021, Clinical Cancer Research.

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.

Matthew J. Frigault, J. Ritz, D. Maloney, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies

M. Mei, Yazeed Samara, 2022, Cancers.

Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

A. Nademanee, L. Kwak, Y. Nieto, 2020 .

The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

R. Vij, Lixin Yang, M. Aljurf, 2022, Haematologica.

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

G. Marcucci, S. Forman, S. Rahmanuddin, 2021, Blood advances.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Lixin Yang, G. Marcucci, I. Aldoss, 2019, Blood advances.

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.

A. Nademanee, A. Krishnan, S. Forman, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

A. Nademanee, L. Kwak, I. Aldoss, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.

C. Jacobson, B. Hill, R. Lynch, 2020, Clinical lymphoma, myeloma & leukemia.

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

T. Larson, J. Friedberg, R. Bordoni, 2019, Blood.

How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT.

M. Mei, Robert Chen, 2018, Clinical lymphoma, myeloma & leukemia.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

A. Nademanee, S. Forman, A. Salhotra, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

G. Marcucci, I. Aldoss, S. Forman, 2019, Bone Marrow Transplantation.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2018, Haematologica.

Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use

G. Marcucci, I. Aldoss, V. Pullarkat, 2018, American journal of hematology.

Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital.

I. Aldoss, V. Pullarkat, Tamer Othman, 2020, Clinical lymphoma, myeloma & leukemia.

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia

G. Marcucci, I. Aldoss, S. Forman, 2019, British journal of haematology.

Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents

G. Marcucci, I. Aldoss, S. Forman, 2021, American journal of hematology.

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

G. Marcucci, I. Aldoss, S. Forman, 2019, Blood advances.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

I. Aldoss, S. Forman, D. Snyder, 2022 .

Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2020, American journal of hematology.

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

G. Marcucci, I. Aldoss, S. Forman, 2020, Leukemia & lymphoma.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2019, American journal of hematology.

T. Slavin, G. Marcucci, I. Aldoss, 2018, Haematologica.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.

A. Nademanee, L. Kwak, Y. Nieto, 2022, The Lancet. Haematology.

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

G. Marcucci, I. Aldoss, P. Curtin, 2022, Blood advances.

PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

S. Kambhampati, T. Siddiqi, A. Salhotra, 2022, Clinical lymphoma, myeloma & leukemia.

Central nervous system lymphoma

M. Mei, 2017 .

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

I. Aldoss, S. Forman, D. Snyder, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.

W. Chan, D. Weisenburger, L. Kwak, 2019, Blood.

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

D. Brander, T. Siddiqi, B. Hill, 2021, Clinical Cancer Research.

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma

F. Awan, M. Perales, C. Jacobson, 2022, Haematologica.

Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

M. Aljurf, R. Gale, L. Lekakis, 2020, Cancer.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

W. Chan, D. Weisenburger, A. LaCasce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.

A. Krishnan, S. Bhatia, G. Somlo, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

A. Nademanee, G. Marcucci, S. Forman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Lixin Yang, G. Marcucci, I. Aldoss, 2021, Blood Cancer Journal.

Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma

N. Ghosh, M. Cairo, U. Farooq, 2020, British journal of haematology.

Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post Autologous Stem Cell Transplant.

J. Wong, S. Kambhampati, S. Dandapani, 2022, International journal of radiation oncology, biology, physics.

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.

W. Chan, D. Weisenburger, A. Nademanee, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Editorial: Advances in the treatment of Hodgkin lymphoma

R. Ramchandren, G. Perini, M. Mei, 2023, Frontiers in Oncology.

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

S. de Vos, R. Furman, P. Barr, 2022, Blood.

Immune thrombocytopenia after immune checkpoint inhibitor therapy

V. Pullarkat, I. Amanam, M. Mei, 2021, British journal of haematology.

Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma

W. Chan, Xiwei Wu, L. Kwak, 2019, Clinical Cancer Research.

Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

A. Amini, S. Kambhampati, S. Sampath, 2023, Cancers.

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma.

A. Nademanee, S. Forman, R. Spielberger, 2023, Clinical lymphoma, myeloma & leukemia.